Intro

Johnson & Johnson (JNJ) stock has been under pressure recently, with the share price down over the past week, month, and past 3 months, prompting investors to reassess what current levels may be pricing in.

Recent trading has been weak, with the share price down 9.14% over the past 90 days. Johnson & Johnson still posts a 7.49% year to date share price return and a 47.95% 1 year total shareholder return, suggesting earlier optimism is now being reassessed as investors weigh growth prospects against perceived risks.

If recent moves in J&J have you rethinking your watchlist, it could be a good moment to scan other healthcare leaders using our screener for 39 healthcare AI stocks

With Johnson & Johnson shares recently weaker but still backed by sizeable revenue and net income, the key question is whether the current valuation reflects a discount on future earnings power or whether the market already prices in future growth.

Most Popular Narrative: 9.6% Undervalued

At a last close of $222.89 versus a narrative fair value of $246.46, Johnson & Johnson is framed as modestly mispriced, with the story centering on consistent earnings power rather than rapid expansion.

Johnson & Johnson represents a high-quality, defensive healthcare leader with resilient earnings, strong cash flow generation, and disciplined capital allocation. Following the Kenvue spin-off, JNJ is now more focused on higher-margin Pharmaceutical and MedTech segments, improving long-term growth visibility.

Want to see what sits behind that fair value gap? The narrative leans heavily on steady top line expansion, firm margins, and a richer earnings multiple. The key is how those three pieces are stitched together over the next few years.

Result: Fair Value of $246.46 (UNDERVALUED)

However, the narrative could be challenged if legal or regulatory issues escalate, or if key pharmaceutical products face sharper than expected competition or pricing pressure.

Another Angle On Valuation

The user narrative points to a fair value of $246.46, yet on earnings multiples Johnson & Johnson is priced quite differently. The stock trades on a P/E of 25.5x, higher than the US pharmaceuticals industry at 14.8x, but slightly below close peers at 26.1x and near a fair ratio of 26.3x. This suggests limited room for error if growth or margins disappoint.

Next Steps

Mixed messages on value and risk so far? Use the data to pressure test the story for yourself and see how it lines up with your expectations, starting with 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If J&J has sharpened your focus, you can use this momentum to scan a wider set of opportunities before the next round of market moves passes you by.

• Target potential mispricings by reviewing companies that screen as high quality and potentially underappreciated using our list of 46 high quality undervalued stocks
• Strengthen your income stream by focusing on companies offering robust payouts through our selection of 11 dividend fortresses
• Reduce portfolio stress by concentrating on companies that rank well on stability through our curated set of 63 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.